New drug combo shows promise for rare salivary gland cancer
NCT ID NCT04895735
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests a combination of two drugs—pemetrexed (chemotherapy) and pembrolizumab (immunotherapy)—in people whose salivary gland cancer has returned or spread. The goal is to see if this combo can shrink tumors or slow the disease. The study includes 45 adults with advanced cancer that cannot be cured by standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.